Abstracts tagged "cytokines"

Abstract Number: 0197 • ACR Convergence 2021
Successful Treatment of Severe COVID-19 Pneumonia with Simultaneous Tocilizumab and Anakinra – A Case Series
Hildrun Haibel¹, Stefan Angermair², Michael Schumann², Janis Vahldiek³, Denis Poddubnyy⁴ and Thomas Schneider², ¹Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Medicine Berlin Campus Benjamin Franklin, Berlin, Germany, ³Charité University Medicine Berlin, Berlin, Germany, ⁴Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Severe and life threating COVID-19 pneumonia is often characterized by local and systemic immune-mediated hyperinflammation At the early disease stage activated monocytes are migrating…
Abstract Number: 1105 • ACR Convergence 2021
Discovering Variants in Suspected Monogenic Systemic Inflammatory Disease: An Adult Case Series
Jason An¹, Madeline Couse¹, Dilan Dissanayake², Daniela Dominguez², Ronald Laxer¹, Christian Marshall¹, Johannes Roth³, Robert Rottapel⁴ and Linda Hiraki², ¹SickKids, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴St Michael's Hospital, Toronto, ON, Canada
Background/Purpose: Monogenic systemic inflammatory diseases (MSID) are a heterogeneous group of rare conditions caused by single gene variants leading to immune dysregulation. Diagnostic yield of…
Abstract Number: 0489 • ACR Convergence 2021
CC-99677: A Novel, Oral, Selective MK2 Inhibitor with Sustainable Multi-Cytokine Inhibition for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Kofi Mensah¹, Rajula Gaur¹, Jamie Connarn¹, Michael Thomas¹, Liangang Liu¹, Stuart Mair², Francisco Ramírez-Valle¹ and Maria Palmisano¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Quotient Sciences, Nottingham, United Kingdom
Background/Purpose: Inhibitors of p38 are associated with tachyphylaxis in patients with RA and other inflammatory diseases, where early reduction in ex vivo production of cytokines,…
Abstract Number: 1386 • ACR Convergence 2021
Measurement of TIMP-1 in Pulmonary Vessels May Be a Novel Marker of Reflecting mPAP in CTD-PH
Shusaku Nakashima¹, Kaori Ishikawa¹, Kiyo Ueeda¹, Tomohiro Kameda¹, Hiromi Shimada¹, Risa Wakiya¹, Mansour mai¹, Mikiya Kato¹, Taichi Miyagi², Koichi Sugihara¹, Rina Semba¹, Mao Mizusaki¹ and Hiroaki Dobashi³, ¹Kagawa University, Takamatsu, Japan, ²Kagawa University, Kidagun, Japan, ³Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan
Background/Purpose: CTD is a disease with immune abnormalities which could alter normal cytokine profile. CTD-PH has a different pathogenesis from that of iPAH, and immunosuppressive…
Abstract Number: 0508 • ACR Convergence 2021
The Impact of Macrophages Stimulated with Malondialdehyde-Acetaldehyde And/or Citrulline Modified Proteins on Fibroblasts Activation
Nozima Aripova, Michael Duryee, Evan Ryan, Peter Maloley, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: In rheumatoid arthritis (RA), chronic synovial inflammation is accompanied by fibrotic responses that together lead to pannus formation and progressive joint damage. Exposure to…
Abstract Number: 1423 • ACR Convergence 2021
Ability of Soluble Immune Mediators and SLE-associated Autoantibody Specificities to Forecast Transition to Classified SLE and Inform a Lupus Classification Risk Immune Index
Melissa Munroe¹, Rufei Lu², Timothy Gross¹, George Tsokos³, Michael Keith⁴, John Harley⁵ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, OUHSC, Oklahoma City, OK, ³BIDMC, Boston, MA, ⁴Inova, Arlington, VA, ⁵US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: SLE is a chronic autoimmune disease driven by immune dysregulation. We have previously identified patterns of disordered immunity present prior to and concurrent with…
Abstract Number: 0510 • ACR Convergence 2021
Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct (MAA) And/or Citrulline (CIT) Induces Unique Cellular Responses in Human RA Synoviocytes
Brittany Wordekemper, Nozima Aripova, Michael Duryee, Eric Daubach, Bryant England, James O'Dell, Ted Mikuls and Geoffrey Thiele, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Malondialdehyde (MDA) is produced in response to oxidative stress and is associated with inflammation and disease pathogenesis. MDA can break down and form acetaldehyde…
Abstract Number: 1429 • ACR Convergence 2021
ALPN-303, an Enhanced, Potent Dual BAFF/APRIL Antagonist Engineered by Directed Evolution for the Treatment of Systemic Lupus Erythematosus (SLE) and Other B Cell-Related Diseases
Stacey Dillon, Lawrence Evans, Katherine Lewis, Jing Yang, Mark Rixon, Joe Kuijper, Daniel Demonte, Janhavi Bhandari, Steven Levin, Kayla Kleist, Sherri Mudri, Susan Bort, Daniel Ardourel, Michelle Seaberg, NinXin Wang, Chelsea Gudgeon, Russell Sanderson, Martin Wolfson, Jan Hillson, Pamela Holland and Stanford Peng, Alpine Immune Sciences, Seattle, WA
Background/Purpose: B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) are TNF superfamily members that bind TACI (transmembrane activator and CAML interactor), BCMA…
Abstract Number: 0511 • ACR Convergence 2021
Tumor Necrosis Factor-α Modulates Endothelial-to-mesenchymal Transition and Increases Protein Tyrosine Phosphatase 1B
Jorge Romo-Tena¹, Jose Esparza-Lopez², Carmelo Carmona-Rivera³, Luz P blanco³, Mariana Kaplan⁴ and María de Jesús Ibarra-Sánchez², ¹INNSZ / NIAMS, Mexico City, Mexico, ²INNSZ, Mexico City, Mexico, ³NIAMS, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD
Background/Purpose: Endothelial dysfunction is a hallmark in the pathogenesis of many inflammatory diseases. The endothelial-to-mesenchymal transition (EndoMT) is a process where endothelial cells lose their…
Abstract Number: 1438 • ACR Convergence 2021
Development of a Computationally Designed, Hyperstable Dual Inhibitor of the IL-2 and IL-15 Receptors: A Novel Therapeutic Candidate for Inflammatory Conditions
Renan Vergara¹, Alex Chen¹, Jerry Chen¹, Marianne Riley¹, Luis Blancas-Mejia¹, Christie Mortales¹, Tania Berrocal¹, Tanu Priya¹, Marsha Mason¹, Kevin Yu¹, Olga Sharapova¹, Jorgen Nelson¹, Alfredo Quijano-Rubio¹, Thomas Linsky¹, Ryan Swanson¹ and Daniel-Adriano Silva², ¹Neoleukin Therapeutics, Inc., Seattle, WA, ²Formerly of Neoleukin Therapeutics, Inc., Seattle, WA
Background/Purpose: T cell mediated pathology is central to many forms of autoimmunity, and cytokines perform critical inflammatory functions during this process. IL-2 and IL-15 are…
Abstract Number: 0512 • ACR Convergence 2021
Peficitinib and Filgotinib Inhibit Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes
Yuzo Ikari, Takeo Isozaki, Kuninobu Wakabayashi and Tsuyoshi Kasama, Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Background/Purpose: Peficitinib and filgotinib are novel Janus kinase (JAK) inhibitors developed for the treatment of rheumatoid arthritis (RA). Peficitinib inhibits all JAKs, especially JAK3. Filgotinib,…
Abstract Number: 1455 • ACR Convergence 2021
IL1β mRNA Expressions in Peripheral Blood Mononuclear Cells Increase and May Associate with Cartilage Damage of the Respiratory Tract Probably Through Matrix metalloproteinase-3 Production in Patients with Relapsing Polychondritis
Jun Shimizu¹, Sueshige Wakisaka¹, Tomoko Suzuki¹ and Noboru Suzuki², ¹St. Marianna University School of Medicine, Kawasaki, Japan, ²St. Marianna University School of Medicine, Kawasaki Kanagawa, Japan
Background/Purpose: Relapsing polychondritis (RP) is an inflammatory disorder that affects cartilage of ears, nose, joints, and respiratory tract. The inflammation often spreads to eyes, cardiovascular…
Abstract Number: 0535 • ACR Convergence 2021
Therapeutic Efficacy of a Biomimetic ALXR Agonist in Murine Systemic Lupus Erythematosus (SLE)
Priyal Dave¹, Tiange Dong¹, Andrew Mead¹, Isaac Asante¹, Brandon Ebright¹, Eugene Zhou¹, RIta Li¹, Nicos Petasis¹, William Stohl² and Stan Louie¹, ¹University of Southern California, Los Angeles, CA, ²University of Southern California Keck School of Medicine, Los Angeles, CA
Background/Purpose: Neutrophils are key initiators and promoters of autoimmunity, including SLE, via the elaboration of neutrophil extracellular traps (NETs). We tested the efficacy of the…
Abstract Number: 1472 • ACR Convergence 2021
Characterization and Function of Tumor Necrosis Factor α and Interleukin-6–Induced Osteoclasts in Rheumatoid Arthritis
Kazuhiro Yokota¹, Kojiro Sato², Yoshimi Aizaki³, Shinya Tanaka⁴, Miyoko Sekikawa⁴, Noritsune Kozu⁵, Yuho Kadono⁴, Hiromi Oda⁶ and Toshihide Mimura⁷, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Jichi Medical University, Tochigi, Japan, ³Saitama Medical University, Saitama, Japan, ⁴Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan, ⁵Kozu Orthopaedic Clinic, Chiba, Japan, ⁶Department of Orthopaedic Surgery, National Hospital Organization Ibusuki Medical Center, Kagoshima, Japan, ⁷Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama, Japan
Background/Purpose: We have previously reported that stimulation of mouse bone marrow–derived macrophages with a combination of tumor necrosis factor α (TNFα) and interleukin-6 (IL-6) induces…
Abstract Number: 0572 • ACR Convergence 2021
Circulating Cytokines and Chemokines Are Associated with the Risk of Incident Cardiovascular Disease in Rheumatoid Arthritis Independent of Conventional Disease Activity Measures
Tate Johnson¹, Michael Duryee², Carlos Hunter², Punyasha Roul², Yangyuna Yang², Joshua Baker³, Geoffrey Thiele², Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in rheumatoid arthritis (RA). While chronic inflammation contributes to CVD pathogenesis, the role of specific…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].